Open Orphan PLC Directorate Change (8623O)
October 13 2021 - 1:00AM
UK Regulatory
TIDMORPH
RNS Number : 8623O
Open Orphan PLC
13 October 2021
13 October 2021
Open Orphan plc
("Open Orphan" or the "Company")
Directorate Change
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in vaccine
and antiviral testing using human challenge clinical trials ,
announces the appointment of Yamin 'Mo' Khan as an Independent
Non-Executive Director to the Board of Open Orphan with immediate
effect. Mo will also Chair both the Audit and Risk and Nomination
Committees.
Mo is a business leader and customer-focused CRO executive with
over 25 years of global clinical research experience across
clinical operations, project management, business development and
executive management functions. He previously worked at Pharm-Olam
International, a global CRO, from 2000-2019 across a variety of
senior positions including Executive Vice President of Clinical
Development and Global Director of Clinical Operations. Mo was a
key leader in driving the expansion and growth of the company from
a small niche European CRO to a global player with offices across
all continents. Laterally, he led global business development at
Pharm-Olam resulting in significant growth and a successful sale in
2017, delivering substantial returns to its shareholders. Prior to
this he worked at Innovex and Quintiles CRO (IQVIA).
As part of Mo joining the Board, Michael Meade is stepping down
from the Board with immediate effect. Michael joined the Board of
Open Orphan as part of the acquisition of hVIVO and helped to steer
the Company to the stronger and more successful position that it
occupies today.
The disclosures required by Schedule 2(g) of the AIM Rules for
Companies and Rule 5.22 (b) of Chapter 5: Additional Rules for the
Euronext Growth Market operated by Euronext Dublin in respect of Mo
are set out in the Appendix to this announcement.
Cathal Friel, Executive Chairman, Open Orphan, said: "We are
delighted to announce the appointment of Mo Khan to the Board of
Open Orphan. Mo has extensive CRO knowledge and experience in a
fast growth business and will be an invaluable addition to the
Company as we capitalise on our position as a leading European CRO
and world leader in testing vaccines and therapeutics for
infectious and respiratory diseases, as this market exponentially
grows to an expected $250bn by 2025.
We would also like to thank Michael Meade for all of his help
and assistance in the 22 months since we acquired hVIVO, Michael's
knowledge of the City and his financial acumen has been invaluable
to us."
Mo Khan, Incoming Non-Executive Director, Open Orphan, said: "I
am delighted to join the Board of Open Orphan. I have been very
impressed by the outstanding progress that Cathal Friel, the Board
and the team have made in such a short period of time. These are
exciting times for Open Orphan and its subsidiaries in the light of
their current full-service, high quality offerings in conjunction
with the increased interest in challenge studies. I look forward to
working with them in the next stage of the evolution of Open
Orphan."
For further information please contact:
Open Orphan plc +353 (0)1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser and
Joint Broker) +44 (0)20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell / Oscair
McGrath
finnCap plc (Joint Broker) +44 (0) 20 7220 500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint Broker) +353 (0)1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)
7502 558 258 / +44 (0) 7747
Paul McManus / Sam Allen / Louis Ashe-Jepson 515393
Appendix
Full name: Yamin Mohammed Khan
Age: 52
Current directorships / partnerships Previous directorships / partnerships (in
the last five years)
None Pharm-Olam International (UK) Limited
Mo Khan does not hold any shares or options over shares in the
Company.
There is no further information to be disclosed in relation to
Mo 's appointment pursuant to AIM Rule 17, paragraph (g) of
Schedule Two of the AIM Rules for Companies or and Rule 5.22 (b) of
Chapter 5: Additional Rules for the Euronext Growth Market operated
by Euronext Dublin.
Notes to Editors
About Open Orphan
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic and its state-of-the-art
24-bedroom QMB clinic with its highly specialised on-site virology
and immunology laboratory. Open Orphan has a leading portfolio of
human challenge study models for infectious and respiratory
diseases and is developing a number of other models. There has been
an explosion in the growth of the infectious disease
pharmaceuticals market, which is estimated to grow to in excess of
$250bn by 2025. The Group is focused on refreshing its existing
challenge models and develop new models, such as Malaria, to
address the dramatic growth potential of the global infectious
disease market.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFFIFWEEFSEDS
(END) Dow Jones Newswires
October 13, 2021 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Apr 2024 to May 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From May 2023 to May 2024